Jpmorgan Chase & CO Neuro Pace Inc Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Neuro Pace Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,816 shares of NPCE stock, worth $37,047. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,816
Previous 32,115
81.89%
Holding current value
$37,047
Previous $423,000
89.83%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NPCE
# of Institutions
57Shares Held
19.8MCall Options Held
28.3KPut Options Held
300-
Kck Ltd. Tortola, D85.62MShares$35.8 Million77.74% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.41MShares$21.7 Million0.62% of portfolio
-
Morgan Stanley New York, NY2.47MShares$15.7 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.43MShares$15.5 Million1.86% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.14MShares$7.29 Million3.99% of portfolio
About NeuroPace Inc
- Ticker NPCE
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 24,846,900
- Market Cap $158M
- Description
- NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...